Target-based genomic profiling of ctDNA from Chinese non-small cell lung cancer patients: a result of real-world data

Circulating free tumor-derived DNA to detect EGFR mutations in patients with advanced NSCLC: French subset analysis of the ASSESS study

(2019) Marc G. Denis et al.   Journal of Thoracic Disease

IASLC Statement Paper: Liquid Biopsy for Advanced Non-Small Cell Lung Cancer (NSCLC)

(2018) Christian Rolfo et al.   Journal of Thoracic Oncology

Primary resistance to osimertinib due to SCLC transformation: Issue of T790M determination on liquid re-biopsy

(2018) R. Minari et al.   LUNG CANCER

Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

(2018) Freddie Bray et al.   CA-A CANCER JOURNAL FOR CLINICIANS

A Multicenter Study to Assess EGFR Mutational Status in Plasma: Focus on an Optimized Workflow for Liquid Biopsy in a Clinical Setting

(2018) Laure Sorber et al.   Cancers

Clinical utility of plasma-based digital next-generation sequencing in patients with advance-stage lung adenocarcinomas with insufficient tumor samples for tissue genotyping

(2018) J Zugazagoitia et al.   ANNALS OF ONCOLOGY

Hybrid Capture–Based Genomic Profiling of Circulating Tumor DNA from Patients with Advanced Non–Small Cell Lung Cancer

(2018) Alexa B. Schrock et al.   Journal of Thoracic Oncology

Subclonal Therapy by Two EGFR TKIs Guided by Sequential Plasma Cell-free DNA in EGFR -Mutated Lung Cancer

(2017) Nir Peled et al.   Journal of Thoracic Oncology

Dabrafenib plus trametinib in patients with previously untreated BRAF V600E -mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial

(2017) David Planchard et al.   LANCET ONCOLOGY

EGFR mutation status in plasma and tumor tissues in non-small cell lung cancer serves as a predictor of response to EGFR-TKI treatment

(2016) Dan Que et al.   CANCER BIOLOGY & THERAPY

Clinical mutational profiling of bone metastases of lung and colon carcinoma and malignant melanoma using next-generation sequencing

(2016) Gang Zheng et al.   CANCER CYTOPATHOLOGY

MonitoringEGFRT790M with plasma DNA from lung cancer patients in a prospective observational study

(2016) Naoko Sueoka-Aragane et al.   CANCER SCIENCE

Detection of Therapeutically Targetable Driver and Resistance Mutations in Lung Cancer Patients by Next-Generation Sequencing of Cell-Free Circulating Tumor DNA

(2016) J. C. Thompson et al.   CLINICAL CANCER RESEARCH

Dabrafenib plus trametinib in patients with previously treated BRAF V600E -mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial

(2016) David Planchard et al.   LANCET ONCOLOGY

Assessing intratumor heterogeneity and tracking longitudinal and spatial clonal evolutionary history by next-generation sequencing

(2016) Yuchao Jiang et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Contribution of KRAS mutations and c.2369C > T (p.T790M) EGFR to acquired resistance to EGFR-TKIs in EGFR mutant NSCLC: a study on circulating tumor DNA

(2016) Marzia Del Re et al.   Oncotarget

Guide to detecting epidermal growth factor receptor (EGFR) mutations in ctDNA of patients with advanced non-small-cell lung cancer

(2016) Nicola Normanno et al.   Oncotarget

Optimised Pre-Analytical Methods Improve KRAS Mutation Detection in Circulating Tumour DNA (ctDNA) from Patients with Non-Small Cell Lung Cancer (NSCLC)

(2016) James L. Sherwood et al.   PLoS One

Performance of Streck cfDNA Blood Collection Tubes for Liquid Biopsy Testing

(2016) Inga Medina Diaz et al.   PLoS One

Broad, Hybrid Capture-Based Next-Generation Sequencing Identifies Actionable Genomic Alterations in Lung Adenocarcinomas Otherwise Negative for Such Alterations by Other Genomic Testing Approaches

(2015) A. Drilon et al.   CLINICAL CANCER RESEARCH

Non–Small Cell Lung Cancer, Version 6.2015

(2015) David S. Ettinger et al.   Journal of the National Comprehensive Cancer Network

Multi-institutional Oncogenic Driver Mutation Analysis in Lung Adenocarcinoma: The Lung Cancer Mutation Consortium Experience

(2015) Lynette M. Sholl et al.   Journal of Thoracic Oncology

ALKRearrangement in a Large Series of Consecutive Non–Small Cell Lung Cancers: Comparison Between a New Immunohistochemical Approach and Fluorescence In Situ Hybridization for the Screening of Patients Eligible for Crizotinib Treatment

(2014) Greta Alì et al.   ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE

Coexistence of EGFR with KRAS, or BRAF, or PIK3CA somatic mutations in lung cancer: a comprehensive mutation profiling from 5125 Chinese cohorts

(2014) S Li et al.   BRITISH JOURNAL OF CANCER

Two Novel ALK Mutations Mediate Acquired Resistance to the Next-Generation ALK Inhibitor Alectinib

(2014) R. Katayama et al.   CLINICAL CANCER RESEARCH

Discovery of a Potent and Selective EGFR Inhibitor (AZD9291) of Both Sensitizing and T790M Resistance Mutations That Spares the Wild Type Form of the Receptor

(2014) M. Raymond V. Finlay et al.   JOURNAL OF MEDICINAL CHEMISTRY

Circulating tumor DNA as a non-invasive substitute to metastasis biopsy for tumor genotyping and personalized medicine in a prospective trial across all tumor types

(2014) Ronald Lebofsky et al.   Molecular Oncology

Comprehensive molecular profiling of lung adenocarcinoma

(2014) Eric A. Collisson et al.   NATURE

Age-Related Clonal Hematopoiesis Associated with Adverse Outcomes

(2014) Siddhartha Jaiswal et al.   NEW ENGLAND JOURNAL OF MEDICINE

Pooled Analysis of the Prognostic and Predictive Effects ofKRASMutation Status andKRASMutation Subtype in Early-Stage Resected Non–Small-Cell Lung Cancer in Four Trials of Adjuvant Chemotherapy

(2013) Frances A. Shepherd et al.   JOURNAL OF CLINICAL ONCOLOGY

Emerging Paradigms in the Development of Resistance to Tyrosine Kinase Inhibitors in Lung Cancer

(2013) Justin F. Gainor et al.   JOURNAL OF CLINICAL ONCOLOGY

Symptom Control and Quality of Life in LUX-Lung 3: A Phase III Study of Afatinib or Cisplatin/Pemetrexed in Patients With Advanced Lung Adenocarcinoma WithEGFRMutations

(2013) James Chih-Hsin Yang et al.   JOURNAL OF CLINICAL ONCOLOGY

EGFR mutation frequency and effectiveness of erlotinib: A prospective observational study in Danish patients with non-small cell lung cancer

(2013) Britta Weber et al.   LUNG CANCER

Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing

(2012) Marco Gerlinger et al.   NEW ENGLAND JOURNAL OF MEDICINE

Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1

(2012) K. Ohashi et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Pretreatment EGFR T790M Mutation and BRCA1 mRNA Expression in Erlotinib-Treated Advanced Non-Small-Cell Lung Cancer Patients with EGFR Mutations

(2011) R. Rosell et al.   CLINICAL CANCER RESEARCH

Mechanisms of Resistance to EGFR TKIs and Development of a New Generation of Drugs in Non-Small-Cell Lung Cancer

(2011) Takayuki Kosaka et al.   JOURNAL OF BIOMEDICINE AND BIOTECHNOLOGY

Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non–Small-Cell Lung Cancers Dependent on the Epidermal Growth Factor Receptor Pathway

(2009) Kim-Son H. Nguyen et al.   Clinical Lung Cancer

EGFR testing in lung cancer is ready for prime time

(2009) Fred R Hirsch et al.   LANCET ONCOLOGY

Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer

(2009) Rafael Rosell et al.   NEW ENGLAND JOURNAL OF MEDICINE